Selegiline Hydrochloride Tablet
NDC 73141-006
Product Information
Selegiline Hydrochloride is a ANDA-approved product labeled by A2a Integrated Pharmaceuticals. This medication is typically used as a monoamine oxidase inhibitor [epc]. It is supplied as a white tablet for oral administration. This product entry covers the primary NDC 73141-006 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
I3;6
Code Structure Chart
Product Details
What is NDC 73141-006?
What are the uses of this product?
What are Active Ingredients of this product?
- SELEGILINE HYDROCHLORIDE 5 mg/1 - A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- SELEGILINE HYDROCHLORIDE (UNII: 6W731X367Q)
- SELEGILINE (UNII: 2K1V7GP655) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- STARCH, CORN (UNII: O8232NY3SJ)
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- MICROCRYSTALLINE CELLULOSE 101 (UNII: 7T9FYH5QMK)
- MICROCRYSTALLINE CELLULOSE 102 (UNII: PNR0YF693Y)
- POVIDONE K25 (UNII: K0KQV10C35)
- STEARIC ACID (UNII: 4ELV7Z65AP)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 859193 - selegiline HCl 5 MG Oral Tablet
- RxCUI: 859193 - selegiline hydrochloride 5 MG Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.